The healthcare sector was the only one in the green, gaining just 0.2% at midday Tuesday, after the S&P/ASX 200 index fell 131.30 points, or 1.5%, to 8,505.10, to the lowest point in five months.

Minutes from the Reserve Bank of Australia's November meeting showed that the increase in inflation in the September quarter was larger than expected, and its monetary policy board affirmed that it was appropriate in this environment for its decisions to "remain cautious and data dependent."

Radiopharm Theranostics (ASX:RAD) received approval from the Bellberry Human Research Ethics Committee in Australia to start its first-in-human phase 1 clinical trial of RAD 402 for the potential treatment of prostate cancer.

The information technology sector plummeted nearly 6%. The Nasdaq composite and S&P 500 indices fell nearly 1% on Wall Street, while the Dow Jones declined over 1%.

Technology One (ASX:TNE), which fell over 16%, reported that its earnings per share in fiscal 2025 rose to AU$0.4173 from AU$0.3603 a year earlier. Total revenue for the year ended Sept. 30 was AU$610 million, up from AU$515.4 million in the same period a year earlier.